Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Rare oncogenic NTRK gene fusions result in uncontrolled TRK signaling leading to various adult and pediatric solid tumors. Based on the architecture of our multi-targeted clinical candidate BPR1K871 (10), we designed and synthesized a series of quinazoline compounds as selective and orally bioavailable type II TRK inhibitors. Property-driven and lead optimization strategies informed by structure-activity relationship studies led to the identification of 39, which showed higher (about 15-fold) selectivity for TRKA over AURA and AURB, as well as potent cellular activity (IC = 56.4 nM) against the KM12 human colorectal cancer cell line. 39 also displayed good AUC and oral bioavailability (F = 27%), excellent in vivo efficacy (TGI = 64%) in a KM12 xenograft model, and broad-spectrum anti-TRK mutant potency (IC = 3.74-151.4 nM), especially in the double-mutant TRKA enzymatic assays. 39 is therefore proposed for further development as a next-generation, selective, and orally-administered type II TRK inhibitor.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejmech.2021.113673 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Case Report: Dramatic response to entritinib in a patient with gastrointestinal stromal tumor positive for fusion.
Front Oncol
August 2025
Department of Internal Medicine, Shaanxi Provincial Cancer Hospital, Xi'an, Shaanxi, China.
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract, with proto-oncogene, receptor tyrosine kinase (c-kit), or PDGFRα mutations detected in around 85% of cases. GISTs without c-kit or platelet-derived growth factor receptor alpha (PDGFRα) mutations are considered wild-type (WT). Recently, some molecular alterations, including neurotrophic tyrosine receptor kinase (NTRK) fusions, have been reported in very few cases of WT GISTs.
View Article and Find Full Text PDFA rare ER-positive secretory breast carcinoma: diagnostic challenges and surgical treatment.
Ann Med Surg (Lond)
August 2025
Department of Pathology, Nepalese Army Institute of Health Sciences, Kathmandu, Nepal.
Introduction: Secretory breast carcinoma (SBC) is a rare, slow-growing type of breast cancer with a good prognosis, accounting for less than 1% of all breast cancers. It is associated with the ETV6-NTRK3 gene translocation and has a triple-negative molecular profile, but unlike most triple-negative breast cancers, it is less aggressive and rarely metastasizes.
Case Presentation: A 47-year-old woman presented with bloody breast discharge and a lump.
Discovery of imidazo[1,2-b]pyridazine derivatives as potent TRK inhibitors for overcoming multiple resistant mutants.
Bioorg Chem
August 2025
National Key Laboratory of Lead Druggability Research, Shanghai Institute of Pharmaceutical Industry Co., Ltd, China State Institute of Pharmaceutical Industry Co., Ltd., Shanghai 201203, China. Electronic address:
Tropomyosin receptor kinases (TRKs), the superfamily of transmembrane receptor tyrosine kinases, have recently attracted extensive attention as promising cancer therapeutic targets since the approval of Larotrectinib, Entrectinib and Repotrectinib by FDA. Herein, we reported the discovery of a series of novel imidazo[1,2-b]pyridazine derivatives as potent second-generation TRK inhibitors. The representative compound 15m potently inhibited TRK, TRK and TRK with IC values of 0.
View Article and Find Full Text PDFDevelopment of PROTACs for targeted degradation of oncogenic TRK fusions.
bioRxiv
June 2025
Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA, 98109, USA.
Chromosomal translocations leading to the fusion of tropomyosin receptor kinases (TRK) with diverse partner proteins have been identified as oncogenic drivers in many adult and pediatric cancers. While first-generation TRK kinase inhibitors, such as entrectinib and larotrectinib, have shown positive responses in TRK fusion-positive cancers, resistance mutations against these inhibitors in the kinase domain limit their efficacy. Second-generation inhibitors are in clinical evaluation, highlighting a need for novel therapeutic modalities to achieve durable suppression of the oncogenic activity of TRK fusions.
View Article and Find Full Text PDFCellular Angiofibroma With Sarcomatous Transformation: Case Report With Molecular Characterization and Review of the Literature.
Int J Gynecol Pathol
July 2025
Department of Pathology, UPMC/University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Cellular angiofibroma is a benign mesenchymal neoplasm which usually occurs in the vulvovaginal or inguinoscrotal areas. Although benign, cellular angiofibroma may rarely undergo sarcomatous transformation. We report a case of vulvar cellular angiofibroma with sarcomatous transformation in a 62-yr-old woman and a literature review of previously reported cases.
View Article and Find Full Text PDF